exas stock price: Complete Guide

EXAS stock price (Exact Sciences Corporation)

As of January 27, 2026, the exas stock price (ticker: EXAS) was reported at $102.52 per share, according to Benzinga. This guide explains what the exas stock price means, where the quote comes from, major historical moves, the fundamentals that influence the stock, analyst coverage, trading characteristics, and practical ways to monitor EXAS — all written for beginners and investors who want neutral, factual context.

Quick reading expectations: you will learn how to read an EXAS quote, where to get real-time vs delayed data, which company events historically moved the exas stock price, and how to track updates using platforms and alerts. Bitget users can monitor related market data and use Bitget Wallet for secure holdings.

Company and ticker overview

Exact Sciences Corporation operates in cancer screening and diagnostics with headquarters in Madison, Wisconsin. The company develops and commercializes molecular diagnostic tests for early detection and treatment guidance, with two of its most notable products being Cologuard (a non-invasive colorectal cancer screening test) and Oncotype DX (a genomic test that helps inform cancer treatment decisions).

The ticker symbol for Exact Sciences is EXAS, and it trades on the Nasdaq exchange. The company sits in the healthcare sector within the diagnostics & research industry. Understanding the exas stock price begins with knowing the business model: recurring test volumes, reimbursement dynamics, regulatory outcomes, and diagnostic adoption rates all feed into revenue expectations and investor sentiment.

Real-time price and key quote data

When you look up the exas stock price, typical fields you will see on a market quote include:

• Last trade price: the most recent price at which a share traded.
• Change and percent change: the price movement versus the previous close.
• Bid and ask: current highest buyer price (bid) and lowest seller price (ask).
• Volume: shares traded during the current trading session.
• Average volume: typical daily shares traded over a set period (e.g., 30 or 90 days).
• Market capitalization: total company value implied by share price × outstanding shares.
• Float: number of shares available for public trading.
• 52-week high / low: range over the past year.

Reliable platforms where investors commonly check the exas stock price and quote fields include Yahoo Finance, CNBC, Google Finance, Nasdaq, TradingView, Zacks, Macrotrends, and brokerage platforms. Note: delayed feeds are common on public sites; for guaranteed real-time data you may need a brokerage or paid data subscription.

Historical price performance

Long-term price history

Long-term analysis of the exas stock price shows multi-year volatility typical for growth-oriented healthcare and diagnostics companies. Major inflection points historically include product launches (e.g., commercialization milestones for Cologuard), clinical study results, FDA decisions or regulatory developments, and significant M&A transactions. For multi-year datasets and chart overlays, sources like Macrotrends and TradingView archive decades of price history and adjusted prices (which account for splits or corporate actions).

Recent price movements

As of January 27, 2026, the exas stock price was reported at $102.52 per share. Recent months of price action were notably influenced by the announcement that Abbott Laboratories intends to acquire Exact Sciences in a reported $21 billion transaction (reported in November 2025). Corporate news of that magnitude typically reduces standalone public trading activity once a deal is announced, but it often causes short-term volatility around regulatory milestones, shareholder votes, and deal-closing updates.

Other short-term drivers that affect the exas stock price include quarterly earnings releases, volume trends for Cologuard testing, updates to reimbursement policies, and competitive or partnership announcements.

Market capitalization and valuation metrics

Market capitalization (market cap) equals the exas stock price multiplied by the company’s outstanding shares. Valuation metrics investors look for include:

• Price-to-earnings (P/E) ratio: may be not meaningful if Exact Sciences has negative trailing earnings; in that case, alternative ratios are used.
• Price-to-sales (P/S) ratio: useful for growth-phase companies with variable earnings profiles.
• Enterprise value (EV) multiples such as EV/Revenue and EV/EBITDA.

You can find these valuation metrics on major finance platforms. Keep in mind that metrics can change quickly as the exas stock price moves and as the company reports new financials.

Financial performance and fundamentals that affect price

Key financial figures that influence the exas stock price include revenue growth (driven by test volumes and new product uptake), gross margins (product mix and operational efficiency), R&D and SG&A spending, profitability (net income or adjusted EBITDA), free cash flow, and balance-sheet items (cash on hand and debt).

Important fundamental drivers:

• Test volume trends and market penetration for Cologuard and Oncotype DX.
• Reimbursement and payer coverage decisions that affect patient access and unit economics.
• Clinical study outcomes and peer-reviewed data that influence clinician adoption.
• Regulatory approvals or safety notices.
• Large corporate events such as mergers, acquisitions, or partnerships.

All these items can materially influence the exas stock price because they change analysts’ estimates and investor expectations.

Analyst coverage and price targets

Analysts publish ratings (e.g., Buy/Hold/Sell) and price targets that can affect the exas stock price when updated. Consensus price targets are aggregated from multiple broker research reports; significant upgrades or downgrades tend to move the share price, especially ahead of or after earnings or major corporate announcements.

Sources that report analyst consensus and target updates include Zacks, CNBC, and broker research summaries available via market-data aggregators. Always check the publication date of analyst notes — a target published before an acquisition announcement may no longer be relevant.

Corporate actions and shareholder returns

Exact Sciences historically has focused its capital allocation on growth and strategic investments in diagnostics. Notable corporate actions that influence per-share metrics include:

• Mergers & acquisitions: for example, the reported acquisition by Abbott (reported November 2025) valued at approximately $21 billion is a major corporate action that directly influences the exas stock price and future trading status.
• Dividends: Exact Sciences has not typically been a dividend-paying company; investors should verify the latest filings and investor relations updates for any change to dividend policy.
• Share buybacks: repurchases reduce float and can support per-share metrics, but their frequency and scale vary based on board authorization and cash priorities.

As of the Abbott announcement, deal-related terms, timing, and regulatory clearances will determine the final impact on the exas stock price and whether the ticker remains publicly traded after deal close.

Trading characteristics and liquidity

The exas stock price liquidity is reflected by average daily volume and the float. Higher average volume generally implies tighter bid-ask spreads and easier order execution. Options liquidity for EXAS varies and is typically more active around earnings or corporate events.

For active traders, monitor:

• Average daily traded shares (30 and 90-day averages).
• Bid-ask spread (important for large orders or limit strategies).
• Options open interest and implied volatility surrounding events.

If you plan to trade or monitor EXAS through Bitget, use Bitget’s market tools for alerts and execution; for custody, Bitget Wallet can be used for supported assets and account security recommendations.

Technical analysis and charting

Technical traders use indicators and chart patterns to interpret the exas stock price:

• Moving averages (50-day, 200-day) to identify trend direction.
• Relative Strength Index (RSI) to gauge overbought/oversold conditions.
• MACD for momentum shifts.
• Support and resistance zones derived from prior swing highs/lows.

Platforms with interactive charts include TradingView and many brokerage platforms. Technical signals should be used alongside fundamentals and event calendars — especially for healthcare names where single clinical or regulatory updates can overwhelm technical patterns.

Major factors and risks affecting EXAS stock price

Business and operational risks:

• Clinical/regulatory outcomes: negative trial results or regulatory delays for diagnostic products can materially move the exas stock price.
• Reimbursement and payer decisions: changes in coverage reduce demand and revenue visibility.
• Competition: competing diagnostic tests or technologies can pressure market share and margins.

Market and event risks:

• Macroeconomic and sector sentiment: healthcare sector rotations and market-wide risk-off events can affect EXAS despite company-specific fundamentals.
• Deal execution and regulatory approvals: with the reported Abbott transaction, regulatory review and antitrust considerations are risks that affect the exas stock price until the deal closes.

Operational risks:

• Manufacturing or supply-chain disruptions that limit test availability.
• Data-security or privacy incidents affecting patient data or testing operations.

These risk categories are common for diagnostic companies and are directly relevant when interpreting movements in the exas stock price.

Notable market events and news impacting price

Historically, items that have driven the exas stock price include:

• Product or commercial milestones for Cologuard and Oncotype DX.
• Clinical study readouts and peer-reviewed publications.
• FDA decisions or regulatory guidance affecting diagnostics.
• M&A activity; notably, in November 2025 Abbott Laboratories announced a proposed $21 billion acquisition of Exact Sciences, which has been a central price driver since the announcement.

As of January 27, 2026, Benzinga reported that Abbott’s shares had reacted to their own quarterly results and guidance; the acquisition announcement involving Exact Sciences was the largest deal reported in the healthcare sector for November 2025. Reporting around Abbott’s results and guidance also had cross-impact on perceptions of the acquisition and related healthcare valuations.

As of January 27, 2026, according to Benzinga, Exact Sciences was reported at $102.52 per share and Abbott’s proposed $21 billion buyout of Exact Sciences (announced November 2025) was a material corporate development influencing the exas stock price. (Source: Benzinga, reported January 27, 2026.)

How to monitor and obtain price data

Where to get the exas stock price and related market data:

• Public finance portals (e.g., Yahoo Finance, Google Finance, CNBC) for quick snapshots and news aggregation. These platforms often display delayed quotes unless you are logged into a brokerage account.
• Exchange pages (Nasdaq) for official listings and corporate filings.
• Charting platforms (TradingView, Macrotrends) for historical charts, multi-timeframe technical overlays, and downloadable datasets.
• Brokerage platforms for real-time quotes, order execution and margin or options trading.

Practical notes:

• Data delay: many free sites show quotes delayed by 15–20 minutes. For real-time execution or decision-making, use a brokerage feed or paid market data service.
• Alerts & watchlists: set price alerts, news alerts, and earnings reminders on your preferred platform. Bitget offers market alerts and watchlist functionality for supported instruments.
• Official filings: review Exact Sciences’ SEC filings and investor relations releases for definitive company disclosures that can materially affect the exas stock price.

See also

• Exact Sciences Corporation (company overview and investor relations)
• Nasdaq (exchange listing information)
• Diagnostics industry competitors and landscape
• Bitget (market monitoring, trading tools and custody solutions)

References and data sources

• Benzinga (market news snapshot and deal coverage) — reporting date noted above.
• Yahoo Finance, CNBC, Google Finance, Nasdaq, TradingView, Macrotrends, Zacks — commonly used market-data platforms for quote fields, historical data, analyst coverage and charting.

Note: when a price or metric is quoted in this article, the timestamp is included. For live trading decisions, consult a licensed broker or the real-time market data feed you use for execution.

Important compliance note: This article is informational and not investment advice. It presents neutral facts about the exas stock price, historical drivers, and where to monitor market data. For trading or portfolio decisions consult a licensed financial professional.

Explore more market tools and monitoring options on Bitget — set alerts, build watchlists, and secure account assets with Bitget Wallet to stay informed about price updates and corporate actions affecting EXAS.